ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $396,000 | -19.8% | 7,700 | -3.8% | 0.21% | +262.1% |
| Q4 2019 | $494,000 | +79.0% | 8,000 | +105.1% | 0.06% | +205.3% |
| Q4 2018 | $276,000 | -75.7% | 3,900 | -70.7% | 0.02% | -70.8% |
| Q3 2018 | $1,136,000 | -67.8% | 13,300 | -69.5% | 0.06% | -71.1% |
| Q1 2018 | $3,527,000 | +84.7% | 43,600 | -17.9% | 0.22% | +90.7% |
| Q2 2017 | $1,910,000 | -59.0% | 53,100 | -64.9% | 0.12% | -60.0% |
| Q1 2017 | $4,660,000 | -27.1% | 151,300 | -20.7% | 0.30% | -43.8% |
| Q4 2016 | $6,391,000 | -24.6% | 190,800 | -40.1% | 0.52% | -23.6% |
| Q3 2016 | $8,475,000 | +31.2% | 318,500 | +8.7% | 0.69% | +13.7% |
| Q2 2016 | $6,462,000 | +202.2% | 293,100 | +302.6% | 0.60% | +179.6% |
| Q1 2016 | $2,138,000 | +325.9% | 72,800 | +423.7% | 0.22% | +232.3% |
| Q3 2015 | $502,000 | -64.5% | 13,900 | -61.2% | 0.06% | -69.5% |
| Q3 2014 | $1,416,000 | +153.3% | 35,800 | +175.4% | 0.21% | +156.6% |
| Q2 2014 | $559,000 | – | 13,000 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |